Nasdaq:US$9.56 (+0.50) | HKEX:HK$15.34 (+0.18) | AIM:£1.50 (+0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)